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Abstract: Among the pharmaceutical options available for treatment of ovarian cancer, 
much attention has been progressively focused on pegylated liposomal doxorubicin (PLD), 
whose unique formulation, which entraps conventional doxorubicin in a bilayer lipidic sphere 
  surrounded by a polyethylene glycol layer, prolongs the persistence of the drug in the   circulation 
and potentiates intratumor drug accumulation. These properties enable this drug to sustain its 
very favorable toxicity profile and to be used safely in combination with other drugs. PLD 
has been already approved for treatment of advanced ovarian cancer patients failing first-line 
platinum-based treatment. Moreover, phase III trials have been already completed, and results 
are eagerly awaited, which hopefully will expand the range of PLD clinical application in this 
neoplasia both in front-line treatment, and in the salvage setting in combination with other drugs. 
Moreover, attempts are continuing to enable this drug to be combined with novel cytotoxic 
drugs and target-based agents. This review aims at summarizing the available evidence and 
the new perspectives for the clinical role of PLD in the management of patients with epithelial 
ovarian cancer.
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Introduction
Epithelial ovarian carcinoma (OvCa) is one of the most common gynecological 
  malignancies, and the fifth most frequent cause of cancer death in women.1 Worldwide, 
more than 190,000 new cases of ovarian cancer are diagnosed each year accounting 
for around 5% of all cancers in women. In 2009, 21,550 new cases were estimated to 
have been diagnosed in the US.1
The standard of care for the management of OvCa patients includes surgery for 
staging and optimal cytoreduction (residual tumor  1 cm) followed by adjuvant 
chemotherapy with a platinum/taxane combination.2,3 However, despite the advances 
in surgical efforts and the achievement of high response rates to front-line treatment, 
OvCa remains the most lethal gynecological malignancy, almost 50% to 75% of cases 
experiencing progression/recurrence of disease, and a 5-year overall survival OS of 
25% to 30% in advanced stage disease.1,3
The major determinants of clinical outcome are represented by the extent of 
residual tumor at primary surgery and sensitivity to platinum-based therapy,4 the latter 
generally being defined according to the duration of the platinum-free interval (PFI). In 
particular, patients are considered platinum resistant if progression/recurrence of dis-
ease occurs during chemotherapy or within 6 months from its completion; in this clini-
cal setting, second-line single-agent chemotherapy with non-platinum drugs results Therapeutics and Clinical Risk Management 2010:6 464
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in short-lived response rates of approximately 10% to 25%, 
regardless of type of drugs used.5 On the other hand, patients 
defined as platinum sensitive, i.e. recurring/  progressing after 
6 months from the end of primary treatment, are   usually 
treated with platinum-based combinations.4,5 Indeed, in 
the context of platinum sensitivity, relapse/progression 
within 6 to 12 months after the administration of primary 
  chemotherapy represents a type of gray zone in terms of 
  platinum   resistance/responsiveness, and this is strongly 
  supported by the clinical evidence in this subset of patients, 
the response rates range between 27% and 33% regardless 
of whether a   platinum-based re-challenge or non-platinum 
drugs are used.6
In any case, besides the extent of response rates, other 
issues have to be taken into account in the choice of   medical 
treatment, whether in front-line or second-line setting, includ-
ing the rate and profile of side effects, especially for drug 
combinations and their impact on patients’ quality of life. 
In this context, among the pharmaceutical options currently 
available for medical treatment of OvCa, greater emphasis 
has been placed progressively on pegylated   liposomal doxo-
rubicin (PLD) (Doxil® in the US; Caelyx® in Canada and 
Europe), which was approved in 1999 by the FDA and in 2000 
by the European Medicines Evaluation Agency (EMEA) as 
single agent for treatment of advanced OvCa patients failing 
first-line platinum-based treatment. Moreover, phase III trials 
have been already conducted, and results from other studies 
are eagerly awaited, exploring the efficacy of PLD in salvage 
setting and in front-line treatment in combination with other 
therapeutic drugs.
This review will focus on the clinical role of PLD in 
the management of patients with epithelial OvCa. A brief 
  summary of the process of PLD development, as well as new 
perspectives on PLD use, will also be provided.
PLD: development, structure,  
and pharmacokinetic features
PLD is a unique formulation of conventional   doxorubicin 
in which the drug is encapsulated in a bilayer lipidic 
sphere7 of approximately 100 nm (Figure 1): in contrast 
to other   nanoparticles, the liposomal shell is surrounded 
by a   polyethylene glycol (PEG) layer which represents a 
hydrophilic protective barrier between the liposome and the 
  microenvironment, which prevents the   interaction between 
circulating proteins and the lipidic bilayer: indeed, this phe-
nomenon facilitates the activation of the reticulo endothelial 
system, thus   leading to the   destruction of the liposomal struc-
ture and release of the free drug.   Therefore, the pegylation 
process plays a relevant role in prolonging the persistence of 
the drug in the circulation. It has also to be acknowledged 
that the size of PLD, while reducing or even preventing the 
extravasation of the drug in normal tissues, whose capillaries 
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Figure 1 Structural form of doxorubicin HCL (A), fully hydrogenated soy phosphatidylcholine (B), and N-2,2-distearoyl-sn-glycerol-3-phosphoethanolamine sodium salt 
(MPEG-DSPE) (C), comprising the STEALTH® liposome structure (D).Therapeutics and Clinical Risk Management 2010:6 465
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have a basal   membrane and share very tight intercellular 
junctions, allows a   facilitated uptake in tumor tissues which 
are characterized by loose capillary   junctions. Finally, the 
absence of a structured lymphatic system in neoplastic tis-
sues prevents PLD being cleared, and potentiates intratumor 
drug accumulation. These properties, which represent the 
rational basis for the exploitation of nanoparticle technology, 
sustain not only one of the major advantages of PLD, ie, lower 
  cardiotoxicity and   gastrointestinal toxicity compared to the 
free drug, but also its well-known pharmacokinetic   features, 
such as long circulation time, minimal (5%) drug   leakage 
from   circulating liposomes, as well as half-lives of approxi-
mately 60 to 80 hours for doses in the range of 35 to 70 mg/m2 
in patients with solid tumors;8,9 this would, in turn, translate, 
as reported by Gabizon et al,9 to a PLD AUC approximately 
250-fold higher than that of the free drug in humans. In 
particular, it has been shown that after PLD   administration 
nearly 100% of the drug in the plasma is in the   encapsulated 
form;   moreover, compared to free   doxorubicin, PLD plasma 
clearance is   dramatically slower (0.1 L/h for PLD vs 45 L/h 
for free   doxorubicin), and its volume of   distribution is very 
small (4 L vs 254 L, respectively).9 The   pharmacokinetics of 
PLD are still being investigated: there seems to be a complex 
  interaction between   pharmacokinetics and   pharmacodynamics 
which could account for some   patterns of toxicity; for instance, 
stomatitis/mucositis is documented more frequently at higher 
peak dose drug level, while cutaneous toxicity depends on 
dose interval or dose   intensity, as shown by recent data show-
ing that repeated PLD   administrations result in cumulative 
inhibition of the   clearance process.10
Advances in nanoparticle technology have fuelled great 
enthusiasm for the possibility of further enhancing the 
selective intratumor accumulation of PLD, and shifting the 
therapeutic index toward more tolerable toxicity profiles: in 
this context, the preliminary observations that recombinant 
serum albumine-conjugated PLD has longer blood circulating 
properties, smaller hepatic and splenic clearance, and more 
important, larger intratumor accumulation than PLD in pre-
clinical models is very encouraging.11
Phase I studies with PLD as single  
agent or in combination
Table 1 summarizes the studies investigating the safety and 
assessing the maximum tolerated dose (MTD) of PLD used as 
a single agent:12–19 different dose escalation and schedules have 
been explored with PLD dose intensities, ranging from 10 to 
15 mg/m2/week. Stomatitis was reported as the most   frequent 
dose limiting toxicity (DLT) at PLD doses  60 mg/m2, while 
at lower doses with schedules  21 days, the most common 
DLT was represented by hand–foot syndrome (HFS). Neu-
tropenia was the DLT in two studies exploring dose-dense 
regimens,12,13 and in a series of 24 patients with pediatric solid 
tumors, treated with PLD doses of 40 to 50 mg/m2 every 28 
days.19 The current PLD dosage as a single agent as indicated 
for ovarian cancer patients is 50 mg/m2 every 28 days.
Among the novel perspectives relative to PLD use, the 
investigation of escalating (15 to 100 mg/m2) doses of PLD 
plus hyperthermic intraperitoneal chemotherapy follow-
ing optimal cytoreduction has been carried out in a phase 
I study including 21 advanced stage solid tumors including 
3 patients with ovarian cancer.20 The most common grade 
3/4 toxicities were superficial wound infections (n = 6), and 
prolonged ileus (n = 2). The most severe complication was 
represented by a post-operative anastomotic leakage requiring   
re-laparotomy.
Given the evidences of a different toxicity profile, PLD 
safety has been also investigated in combinations involving 
two or even three agents:21–64 in the dose-  finding studies 
exploring combinations of PLD with cisplatin (CDDP) 
(Table 2), the DLTs were mostly represented by mucositis, and 
also neutropenia when CDDP was used at doses  60 mg/m2 
every 28 days.21,22 Similarly, when combining PLD with 
Table 1 Phase I studies with pegylated liposomal doxorubicin as a single agent
Author No. pts Type of tumor MTD DI mg/m2/week DLTs
Bogner12 40 Kaposi sarcomas 20 mg/m2, q15 10 neutropenia
James13 15 Kaposi sarcomas 20 mg/m2, q15 10 hematologic
Uziely14 56 Solid tumors 60 mg/m2, q28 15 stomatitis (doses  60 mg/m2) for 
a single dose HFS (  interval  28 d)
Jahanzeb15 24 Solid tumors 40–50 mg/m2, q28 10–12.5 neutropenia
Gabizon16 22 MBC 50 mg/m2, q28 12.5 stomatitis (doses  60 mg/m2) 
HFS (interval  21 d)
Caponigro17 24 Head/neck 45 mg/m2, q21 15 stomatitis
Hamilton18 20 MBC 60 mg/m2, q42 10 mucositis
Marina19 22 Pediatric solid tumors 60 mg/m2, q28 15 mucositis
Abbreviations: DI, dose intensity; DLT, dose limiting toxicity; HFS, hand–foot syndrome; MBC, metastatic breast cancer; MTD, maximum tolerated dose; q, every; d, day.Therapeutics and Clinical Risk Management 2010:6 466
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carboplatin (JM8), DLTs consisting in stomatitis/mucositis 
were documented at PLD doses  50 mg/m2, while 
thrombocytopenia was the most frequently reported DLT 
for lower PLD doses, with the exception of the study by   
Hamilton et al.25
The MTD of oxaliplatin (OXA) combined with fixed 
doses of PLD as salvage treatment of pre-treated advanced 
ovarian cancer was 130 mg/m2, as 2 out of 3 patients of this 
cohort showed dose-limiting thrombocytopenia and/or neu-
tropenia during the first cycle of treatment.28
For the combination of PLD/taxanes29–46 (Table 3), the 
tolerability of PLD (at doses ranging from 30 to 40 mg/m2) 
combined with paclitaxel (PTX) (135 to 200 mg/m2 every 
21 days) was acceptable; similarly, PLD at doses of 30 
to 40 mg/m2, plus docetaxel (DTX) at doses of 67.5 to 
80 mg/m2, was reported as the MTD for this combination. 
Based on the hypothesis that weekly administration could 
limit toxicity while keeping the dose intensity unchanged, 
weekly or   bi-weekly administration of PLD (doses from 10 to 
20 mg/m2) plus weekly PTX has been also explored.32,34–36
For weekly administration of PLD and DTX the MTDs 
corresponded to PLD 20 mg/m2 and DTX 25 mg/m2, every 28 
days.43 The DLTs were mostly mucositis and neutropenia.
Given the peculiar not overlapping toxicity profile as 
well as the different mechanism of action of PLD compared 
to platinum agents and taxanes, it is not surprising that PLD 
tolerability has been also explored in combination with the 
most active regimen in ovarian cancer:47–49 the addition of 
PLD to JM8/PTX led to defining the MTD as correspond-
ing to JM8 AUC 6, and PTX 175 mg/m2 every 21 days, plus 
PLD 30 mg/m2 administered, as recommended, every other 
cycle. With this 3-drug regimen the same pattern of DLTs 
documented with the doublets was reported. Given the strong 
biological rationale of combining PLD, an inhibitor of topoi-
somerase II, with topoisomerase I inhibitors, as well as the 
non-overlapping toxicity profile of these two classes of drugs, 
the safety of PLD/topotecan (TPT) combination has been the 
subject of active investigation50–60 (Table 5). The MTD was 
reached at PLD doses of 30 and 40 mg/m2, every 21 or 28 
days, and at TPT doses (0.5 to 1.0 mg/m2/day) administered 
with the classic shorter courses (days 1 to 3 or days 1 to 5). 
DLTs were represented in the vast majority of the studies by 
hematological toxicity. On the other hand, the use of longer 
courses (days 1 to 14, days 1 to 21), or longer intervals (up 
to 5 weeks) seemed to be associated with a higher tolerability 
profile.
PLD safety has been investigated also in combination 
with other chemotherapeutics such as etoposide, vinorelbine, 
and gemcitabine;61–63 however, in spite of generally positive 
reports, only a few combinations have progressed to phase 
II evaluation (see below).
Phase II studies with PLD as single  
agent or in combination
A summary of phase II studies using PLD as single agent in 
ovarian cancer is presented in Table 6.65–80
Table 2 Phase I studies with pegylated liposomal doxorubicin in combination with platinum agents
Author No. pts Type of tumor MTD DLTs
Klein21 25 Solid tumors CDDP 50 mg/m2, d8
PLD 50–60 mg/m2, d1, q28
mucositis
skin toxicity
Lyass22 24 Solid tumors CDDP 60 mg/m2,
PLD 50 mg/m2, q28
mucositis
neutropenia
Uys23 19 Solid tumors JM8 AUC 5
PLD 50 mg/m2, q28
stomatitis
neutropenia  
thrombocytopenia
Goncalves24 22 Solid tumors JM8 AUC 5, q21,28
PLD 35 mg/m2
neutropenia
thrombocytopenia
Hamilton25 20 Solid tumors JM8 AUC 6
PLD 30 mg/m2, q21
none
Gonzalez- 
Billalabeitia26
26 Ovarian cancer JM8 AUC 5
PLD 40 mg/m2, q28
mucositis
thrombocytopenia
du Bois27 36a Ovarian, peritoneal,  
tubal cancer
JM8 AUC 6
PLD 40 mg/m2, q28
neutropenia
thrombocytopenia  
abdominal pain emesis, DVT
Recchia28 20 Ovarian cancer OXA 120 mg/m2
PLD 40 mg/m2, q21
neutropenia
thrombocytopenia
Abbreviations: CDDP, cisplatin; DLT, dose limiting toxicity; DVT, deep venous thromboembolism; JM8, carboplatin; MTD, maximum tolerated dose; OXA, oxaliplatin; q, every; d, day.
a24 cases for phase I, 12 cases for confirmatory study.Therapeutics and Clinical Risk Management 2010:6 467
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When considering the studies including only or a very 
large proportion of platinum-resistant patients, the response 
rates ranged from 9.1% to 40.0%, and did not seem to present 
a schedule or dose dependence, although the relatively small 
sample series, and also patients’ heterogeneity in terms of the 
number of previously administered lines of chemotherapy, 
are a major limit to reliable comparisons.
In particular, several studies have shown that a more 
acceptable toxicity profile in terms of decreased rates of HFS 
and stomatitis/mucositis can be obtained with a PLD dose 
of 40 mg/m2 every 28 days, with comparable response rates 
and outcome.67,74,75
More recently, biweekly schedules have also been inves-
tigated in the same clinical setting in order to further improve 
Table 3 Phase I studies with pegylated liposomal doxorubicin (PLD) in combination with taxanes
Author No. pts Type of tumor MTD DLTs
Israel29 – Solid tumors PTX 135 mg/m2, d1,8  
PLD 30 mg/m2 d1, q28
mucositis, skin toxicity  
  neutropenia
Muggia30 25 Endometrial cancer PTX 75 mg/m2, d1,8,15  
PLD 24 mg/m2, d1, q28
HFS
neutropenia
Modiano31 32 Breast,  
gynecologic tumors
PTX 175 mg/m2  
PLD 30 mg/m2, q21
HFS
neutropenia
Schwonzen32 21 MBC PTX 80 mg/m2 weekly  
PLD 15 mg/m2, q15
mucositis, skin toxicity  
alopecia, neurotoxicity
Tolis33 21 – PTX 85 mg/m2, d1,8,15  
PLD 30 mg/m2, d1, q28  
or  
PTX 70 mg/m2, d1,8,15  
PLD 35 mg/m2, d1, q28
neutropenia
Androulakis34 19 Solid tumors PTX 80 mg/m2, d1,8,15,21  
PLD 10 mg/m2, d1,8,15,21, q42
neutropenia  
diarrhea
Mavroudis35 26 Solid tumors PTX 115 mg/m2, d2  
PLD 15 mg/m2, d1, q15
neutropenia
Lortholary36 16 MBC PTX 80 mg/m2, weekly  
PLD 12.5–22.5 mg/m2, q15
–
Briasoulis37 44 Solid tumors PTX 80 mg/m2 d1,8,15  
PLD 35 mg/m2 q28  
or  
PTX 90 mg/m2 d1,8,15  
PLD 30 mg/m2 q28
DVT  
HFS  
neutropenia
Hirsch38 17 Solid tumors DTX 67.5 mg/m2, d1  
PLD 30 mg/m2, d1, q21
Stomatitis, neutropenia   
  thrombocytopenia
Drinkard39 6 Solid tumors DTX 50 mg/m2, d5  
PLD 30 mg/m2,d1, q21/28
esophagitis  
neutropenia
Pavlick40 26 Solid tumors DTX 80 mg/m2  
PLD 30 mg/m2, q21 + GF
HFS  
neutropenia
Tauer41 21 Solid tumors DTX 70 mg/m2,  
PLD 40 mg/m2, q28
neutropenia
Sparano42 41 Breast cancer DTX 60 mg/m2,  
PLD 30 mg/m2, q21  
or  
DTX 75 mg/m2,  
PLD 30 mg/m2, q28 + GF
neutropenia
Sikov43 22 Solid tumors DTX 25 mg/m2, d1,8,15  
PLD 20 mg/m2, d1, q28
mucositis, diarrhea  
neutropenia
Gasparini44 15 Breast cancer DTX 35 mg/m2, d2,9  
PLD 35 mg/m2, d1, q21
skin toxicity  
neutropenia
Fracasso45 22 Solid tumors DTX 40 mg/m2,  
PLD 20 mg/m2, bi-weekly
skin toxicity  
thrombocytopenia
Bischoff46 12 MBC DTX 30 mg/m2, d1,8,15  
PLD 40 mg/m2, d1, q28
neutropenia
Abbreviations: DLT, dose limiting toxicity; DTX, docetaxel; DVT, deep venous thromboembolism; GF, growth factor support; HFS, hand–foot syndrome; MBC, metastatic 
breast cancer; MTD, maximum tolerated dose; PTX, paclitaxel; q, every; d, day.Therapeutics and Clinical Risk Management 2010:6 468
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the toxicity pattern.77–79 Although the direct comparison 
across non-randomized phase II studies is difficult, it seems 
that the biweekly regimen represents a good therapeutic 
option since it does not worsen clinical outcome while pre-
venting severe hematological and non-hematological side 
effects.80 Results relative to platinum-sensitive recurrent 
ovarian cancer patients are not informative or refer to very 
low numbers of cases.69,76,78
The demonstrated efficacy of PLD in the poor prognosis 
subset of recurrent platinum-resistant ovarian cancer has 
supported the investigation of PLD/platinum doublets also 
in platinum-sensitive disease in which the currently admin-
istered partners of platinum agents are generally associated 
with elevated neurologic and hematological toxicity.81,82 As 
shown in Table 7, the association of PLD (50 mg/m2) with 
CDDP (60 mg/m2) was investigated in a 28-day schedule by 
Tas et al,83 who reported an overall response rate of 62.0% 
with 4 (19.0%) complete, and 9 (43.0%) partial responses. 
Although this schedule was well tolerated (only 10% grade 
2 neurotoxicity, and grade 3/4 anemia, neutropenia, and HFS 
accounting for 18%, 41%, and 9%, respectively), PLD/JM8 
combinations are considered more manageable due to the 
Table 4 Phase I studies with pegylated liposomal doxorubicin (PLD) in combination with platinum/taxanes
Author No. pts Type of tumor MTD DLTs
Eng47 23 Solid tumors CDDP 60 mg/m2  
PTX 90 mg/m2 (1 cycle) then 130 mg/m2  
PLD 30 mg/m2, q21
neutropenia
Rose48 12 Ovarian, tubal peritoneal cancer JM8 AUC 5  
PTX 175 mg/m2, q21  
PLD 30 mg/m2, every other cycle
neutropenia
Gibbs49 31 Ovarian carcinomas and MMMT JM8 AUC 6  
PTX 175 mg/m2  
PLD 30 mg/m2, q28  
or  
JM8 AUC 5
PTX 175 mg/m2  
PLD 20 mg/m2, q21
neutropenia   
stomatitis  
HFS
Abbreviations: CDDP, cisplatin; DLT, dose limiting toxicity; HFS, hand–foot syndrome; JM8, carboplatin; MMMT, mixed malignant Müllerian tumors; MTD, maximum tolerated 
dose; PTX, paclitaxel; q, every; d, day.
Table 5 Phase I studies with pegylated liposomal doxorubicin (PLD) in combination with topotecan (TPT)
Author No. pts Type of tumor MTD DLTs
Ryan50 9 Ovarian  
cancer
TPT 1.0 mg/m2, d1-5  
PLD 20 mg/m2, q28
neutropenia  
thrombocytopenia
Yeung51 15 Solid  
tumors
TPT 1.0 mg/m2, d1-5  
PLD 30 mg/m2, q21
mucositis  
neutropenia
Hochster52 17 Solid  
tumors
TPT 0.4 mg/m2, d1-21  
PLD 30 mg/m2, q28
neutropenia
Hamilton53 27 Solid  
tumors
TPT 0.4 mg/m2, d1-21  
PLD 30 mg/m2, q28
neutropenia
Geertsen54 20 Ovarian  
cancer
TPT 0.75 mg/m2, d1-5  
PLD 30 mg/m2, d8, q35
neutropenia
Pautier55 16 Solid  
tumors
TPT 0.5 mg/m2, d1-5  
PLD 35 mg/m2, q28
neutropenia
Mirchandani56 21 Ovarian  
cancer
TPT 0.4 mg/m2, d1-14  
PLD 40 mg/m2, q28
neutropenia  
thrombocytopenia
Garcia57 32 Solid  
tumors
TPT 1.0 mg/m2, d1-3  
PLD 40 mg/m2, d4, q28
neutropenia  
1 death
Ghesquieres58 23 Solid  
tumors (84% ovarian cancer)
TPT 0.5 mg/m2, d1-5  
PLD 35 mg/m2, d1, q28
neutropenia
Rose59 22 Ovarian, tubal  
peritoneal  
cancer
TPT 1.5 mg/m2, d1-5 per os  
PLD 40 mg/m2, d1, q28
neutropenia
Penson60 18 Müllerian  
tumors
TPT 0.5 mg/m2, d1-3  
PLD 30 mg/m2, d1, q21
neutropenia
Abbreviations: DLT, dose limiting toxicity; MTD, maximum tolerated dose; TPT, topotecan; q, every; d, day.Therapeutics and Clinical Risk Management 2010:6 469
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expected lower neurotoxicity.84–89 In 2007 Ferrero et al87 
evaluated PLD (30 mg/m2) followed by JM8 (AUC 5), every 
28 days, in 104 patients, of whom 53 were totally and 43 were 
partially platinum sensitive: overall, the objective response 
rate was 62.5%, with a 38% rate of complete response; 
median progression-free survival (PFS) and OS were 9.4 
months, and 32 months, respectively. Comparable rates of 
response were achieved in the study by duBois et al87 who 
reported an objective response rate of 68% in 67 recurrent 
ovarian cancer patients.
Since platinum sensitivity is more likely to be a continuum 
instead of being defined by operational time-based cut-off 
points, it is not surprising that much interest has been focused 
on that subset of partially platinum = sensitive patients which 
show a substantially similar rate of response to platinum, 
as well as to non-platinum agents,6 thus questioning if they 
should really be considered as partially platinum sensitive 
or partially platinum resistant. The studies by Ferrero et al87 
and by Weber et al89 do not report the specific response rates 
in partially vs totally platinum-sensitive disease, but median 
PFS was longer in the latter group in both studies. The same 
trend has been reported by Rapoport et al,86 who documented 
in the whole population an overall response rate of 67.5% , 
but clearly distinguished totally vs partially sensitive patients 
(response rate = 81.0% vs 52.6%; median PFS = 15.1 vs 9.7 
months, respectively).
The largest phase II study (n = 58) specifically focusing 
on partially sensitive recurrent ovarian cancer reported an 
overall response rate of 46% (4% complete and 42% partial 
responses), with an additional 33% of cases experienc-
ing disease stabilization longer than 6 months.88 For those 
patients with measurable Ca125 levels, the response rate 
was 66% (28% complete and 38% partial responses), with 
an additional 18% of cases experiencing disease stabiliza-
tion longer than 6 months. Median PFS was 10 months, and 
median OS 19.1 months. On the basis of the present litera-
ture, it seems that phase III randomized studies comparing 
platinum-based vs non-platinum agents in this clinical subset 
are urgently needed in order to correctly allocate patients to 
salvage treatment. In this context, a multicentric phase III 
study (MITO-8, NCT00657878) has been recently launched 
comparing PLD (40 mg/m2 every 28 days) vs JM8/PTX 
Table 6 Phase II studies with pegylated liposomal doxorubicin as single agent
Author Dose, schedule Clinical  
setting
RR  
(%)
PFS (Median)  
months
Grade 3/4 toxicity/patient
Hgb Neu PLT HFS
Muggia65 50 mg/m2, q21 RES 35 25.7 5.7 – – – –
Gordon66 50 mg/m2, q21 ALL 89 16.8 4.8 20.2 15.7 2.2 20.2
RES 82 18.3 4.4
Rose67 50 mg/m2, q28 RES 37 13.5 4.0 – – – –
40 mg/m2, q28 RES 39 7.7 4.0
Arcuri68 50 mg/m2, q28 ALL 30 26.6 – – 23.3 – 10.0
Katsumata69 50 mg/m2, q28 RES 63 20.9 5.6 17.6 67.5 6.9 16.2
SEN 11 27.3 5.3
Gorumlu70 50 mg/m2, q28 RES 17 17.0 3.7 – 12.0 – 6.0
Steppan71 45 mg/m2, q28 RES 29 30.5 – – – – –
Chou72 45 mg/m2, q28 RES 29 23.1 5.4 – – – –
Markman73 40 mg/m2, q28 RES 44 9.1 – – 2.0 0 0
Campos74 40 mg/m2, q28 ALL 72 27.0 5.3 11 2 1 –
RES 29 29.0
SEN 43 25.6
Wilailak75 40 mg/m2, q21 RES 14 23.0 6.0 0 14.3 0 2.0
Lorusso76 35 mg/m2, q21 ALL 13.5 7.2 0 10.8 0 2.7
RES 17a 18.9 –
SEN 20 10.0 –
Strauss77 20 mg/m2, q15 RES 50 40 4.1 0 4 0 2.0
Oskay-Oezcelik78 20 mg/m2, q15 RES 7 0 2.3 5 0 0 5.0
SEN 13 7.7 4.1
Sehouli79 20 mg/m2, q15 ALL 64 10.9b 4.3 4.7 0 1.6 4.7
RES 21 – –
SEN 43 – –
Abbreviations: ALL, ; HFS, hand–foot syndrome; Hgb, anemia; PFS, progression-free survival; RR, response rate; RES, platinum-resistant recurrent disease; Neu, neutropenia, 
PLT, platelet toxicity; SEN, platinum-sensitive recurrent disease; q, every; d, day.
aPlatinum sensitivity according to the cut-off of 12-month platinum free interval; bIn assessed patients (n = 44).Therapeutics and Clinical Risk Management 2010:6 470
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(AUC 5, 175 mg/m2) with cross-over on progression in OvCa 
patients recurring within 6 to 12 months from the completion 
of primary treatment.
Overall, the toxicity rate/severity related to combinations 
of PLD and JM8 was consistent across the studies, with 
grade 3/4 anemia ranging from 7% to 13%,84–89 and grade 
3/4 neutropenia occurring in around 50% of cases with the 
exception of two studies.86,88 The rate of severe thrombocyto-
penia seems closely related to PLD dosage: indeed, in studies 
using PLD at 30 to 40 mg/m2, grade 3/4 thrombocytopenia 
remained within 14% and 26%, while at PLD doses of 
50 mg/m2 it increased to approximately 40%. As expected, 
severe HFS was negligible in studies using PLD at a dosage 
of 30 mg/m2.87–89
Combinations of PLD with OXA seem very promising 
since the reported rates of response appear in the range of those 
reported with PLD/JM8 combinations.90–92 Moreover, with the 
limits of the sample size, a very acceptable rate of stomatitis/
mucositis and HFS has been shown, likely due to the use of 
the PLD at the dosage of 30 mg/m2, every 21/28 days.
For neurotoxicity, grade 2 sensory neuropathy was reported 
in 7% of cases in the study by Nicoletto et al90 which seems 
quite an acceptable figure considering that 37% of patients 
had already received 1 previous lines of chemotherapy; 
77% of patients had also been administered prior platinum/
taxanes. However, a high rate of grade 2 neurotoxicity was 
documented by Recchia et al91 whose study, nevertheless, used 
a cumulative OXA dosage of 120 mg/m2.
Attempts to add PLD to combinations of two drugs have 
been also reported: in particular, Valerio et al92 explored 
the combination PLD (30 mg/m2), OXA (85 mg/m2), and 
cyclophosphamide (750 mg/m2) on a 3-week schedule in a 
series of 39 recurrent ovarian cancer patients (12 platinum 
sensitive, 27 platinum resistant). The response rate was 66.3% 
in platinum-sensitive (median PFS 8.5 months), and 37% 
in platinum-resistant (median PFS = 7 months). Overall, 
the regimen was well tolerated with grade 2 neurotoxicity 
observed in 20% of patients, and grade 3/4 anemia, neutro-
penia, and thrombocytopenia documented in 17%, 15%, and 
15% of cases, respectively. Severe HFS was not reported.
Finally, a phase II front-line study (S9912) has been 
recently conducted by the Southwest Oncology Group, which 
investigated the addition of intravenous (iv) PLD (30 to 
40 mg/m2, day 8, × 2 cycles) to intraperitoneal (ip) CDDP 
Table 7 Non-randomized studies with combinations of pegylated liposomal doxorubicin (PLD) and platinum agents
Author Drugs/dose PFI  
mts
No. pts RR  
(%)
PFS  
mts
% Grade 3/4 toxicity/patient
Hgb Neu PLT HFS
Tas83 PLD (50 mg/m2) d1  
CDDP (60 mg/m2) d1, q28
6 22 62.0 – 18 41 0 9
Vorobiof84 PLD (50 mg/m2) d1  
JM8 (AUC 5) d1, q28
6 29 76.2 9 52.3 38 9.5
du Bois85 PLD (40 mg/m2) d1  
JM8 (AUC 6) d1, q28
6 67 68 11.6 8 24 14 7
Rapoport86 PLD (50 mg/m2) d1  
JM8 (AUC 5) d1, q28
All  
7–12  
12
40  
19  
21
67.5  
52.6  
81.0
11.9  
9.7  
15.1
10 55 42.5 7.5
Ferrero87 PLD (30 mg/m2) d1  
JM8 (AUC 5) d1, q28
All  
7–12  
12
96  
43  
53
62.5  
–  
–
9.4  
7.9  
11.4
12 51 26 0
Power88 PLD (30 mg/m2) d1  
JM8 (AUC 5) d1, q28
7–12 58 46 10 7 21 17 1.7
Weber89 PLD (30 mg/m2) d1  
JM8 (AUC 5) d1, q28
6  
6–12  
12
81  
32  
49
65.4  
–  
–
13.6  
9.8  
14.4
13.0 55.0 29.0 1.0
Nicoletto90 PLD (30 mg/m2) d1  
OXA (70 mg/m2) d1, q28
6  
6
14  
29
28.6  
66.7
5.9  
9.9
0 9.3 0 0
Recchia91 PLD (20 mg/m2) d1,2  
OXA (60 mg/m2) d1,2, q21
6  
6
13  
27
32.5  
67.5
5.8  
12.1
5 38 8 0
Valerio92 PLD (30 mg/m2)  
OXA (85 mg/m2)  
cyclophosphamide (750 mg/m2)
6  
6
27  
12
37.0  
66.3
7 
8.5
17 15 15 0
Abbreviations: CDDP, cisplatin; HFS, hand–foot syndrome; Hgb, anemia; JM8, carboplatin; Neu, neutropenia; PFI, platinum-free interval; PFS, progression-free survival; PLT, 
platelet toxicity; RR, response rate; OXA, oxaliplatin; q, every; d, day.Therapeutics and Clinical Risk Management 2010:6 471
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(75 mg/m2, day 2, every 21 days), and both iv and ip 
  paclitaxel (135 mg/m2, day 1, every 21 days, and 60 mg/m2, 
day 8, every 21 days, respectively).93 This regimen gave clini-
cal outcome measures similar to those reported in comparable 
patient populations treated with classical CDDP-containing 
combinations; however, an unacceptable rate of severe toxic-
ity (5 treatment related deaths, and 32 patients with at least 
on grade 3–5 toxicity) was documented, thus discouraging 
any further development.
One of the most frequently studied partners in PLD-based 
combination is represented by gemcitabine (GEM), on the 
basis of the demonstrations of the synergistic antiproliferative 
activity of the drugs, and of their non overlapping toxicity 
profiles. As summarized in Table 8, in the subset of platinum 
resistant disease the response rate range from 22 to 33%, 
with median PFS from 2.7 to 6.0 months regardless of the 
schedule administered.94–100
Considering that the percentage of patients who had 
already received 1 lines of chemotherapy was high in some 
studies,99,100 the regimen was relatively well tolerated: indeed, 
grade 3/4 anemia was documented at 3% to 9% in studies 
using the classical 3-week and 4-week schedules, increasing 
up to 17% in the only study using the bi-weekly schedule.94 
Grade 3/4 neutropenia was negligible in bi-weekly regimens 
but increased up to 30% in the 3-week schedule.99,100 The 
rate of grade 3/4 thrombocytopenia was consistent across all 
studies, at around 9% to 10%, while a wide heterogeneity in 
the rate of severe HFS was noted. However, it has to be taken 
into account that the two studies reporting 10% grade 3/4 
HFS99,100 included heavily pretreated patients in 50% of the 
sample series: indeed, evidence has been reported that the 
incidence of HFS is correlated with the presence of neuropathy 
and also with the number of previous chemotherapy regimens, 
regardless of type of chemotherapeutic agent used.101
Some phase II studies explored the efficacy of PLD asso-
ciated with topotecan,102 as well as PTX,103 vinolrebine,104 
and ifosphamide.105 Overall, the rate of response ranged from 
28% to 37% with a median PFS of 5.5 to 7.5 months, figures 
Table 8 Non-randomized studies with combinations of pegylated liposomal doxorubicin (PLD) and non-platinum agents
Author Drugs/dose No. RR  
(%)
PFS  
mts
% Grade 3/4 toxicity/patient
Hgb Neu PLT HFS
Tas94 PLD (20 mg/m2) d1,15  
GEM (2000 mg/m2) d1,15 q28
RES 18 28.0 – 16.7 0 0 5.5
Skarlos95 PLD (25 mg/m2) d1  
GEM (650 mg/m2) d1,8 q28
RES 37 22 2.7 – – – 2.7
Holloway96 PLD (25 mg/m2) d1  
GEM (650 mg/m2) d1,8
ALL 25 64.0 – – 24.0 4.0 –
Karaoglu97 PLD (25 mg/m2) d1  
GEM (1000 mg/m2) d1,8 q28
RES 35 28.6 6 2.9 8.6 – 0
Petru98 PLD (30 mg/m2) d1  
GEM (650 mg/m2) d 1,8 q28
RES 31 33.0 3.8 3.0 26.0 10 3.0
D’Agostino99 PLD (30 mg/m2), d1  
GEM (1000 mg/m2), d1,8 q21
RES 36  
SEN 31
25.0  
45.2
– 7.0 32.6 8.5 10
Ferrandina100 PLD (30 mg/m2), d1  
GEM (1000 mg/m2), d1,8 q21
RES 66  
SEN 45
21.6  
53.7
5  
8.7
9.0 28.8 10.8 14.4
Verhaar-Langereis102 PLD (30 mg/m2), d1  
TPT (1.0 mg/m2), d1-5 q21  
and PLD (40 mg/m2), d1  
TPT (0.75 mg/m2), d1-5 q21
RES 27 28.0 7.5 – 70.4a 48.1 44.4
Campos103 PLD (30 mg/m2), d1, q21  
PTX (70 mg/m2), weekly  
for 18 weeks
ALL 37  
RES 24  
SEN 13
29.0  
17.0  
54.0
– 2.5 40.0 0 52.5
Katsaros104 PLD (30 mg/m2), d1  
vinorelbine (30 mg/m2), d1, q21
ALL 30 37.0 5.5 0 4.0 0 2.0
Joly105 PLD (40 mg/m2), d1  
ifosfamide (1700 mg/m2), d1-3 q28
ALL 98  
RES 57  
SEN 41b
28.0  
19.0  
41.0
– 7.0 48.0 3.0 2.0
Abbreviations: GEM, gemcitabine; HFS, hand–foot syndrome; Hgb, anemia; Neu, neutropenia; PFS, progression free survival; RR, response rate; RES, platinum resistant   recurrent 
disease; SEN, platinum sensitive recurrent disease; PLT, platelet toxicity; PTX, paclitaxel; TPT, topotecan; q, every; d, day.
aleukopenia; bplatinum-sensitive patients are defined as having a 6–12-month platinum free interval.Therapeutics and Clinical Risk Management 2010:6 472
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which are quite comparable to those reported with other 
non-  platinum combinations. The combination PLD/weekly 
PTX was well tolerated, as was the PLD/vinorelbine 
  combination.104 In contrast, PLD/TPT, even if tested at 
  different doses of the two drugs, was characterized by an 
unacceptable rate of severe anemia (48%), leukopenia (70%), 
and thrombocytopenia (44%).102
PLD: phase III studies
Table 9 summarizes the results from randomized tri-
als using PLD alone or in combination in the salvage 
setting:106–110,112,113,117 in the study by O’Byrne et al,106 214 
recurrent ovarian cancer patients (not defined according 
to platinum sensitivity) were randomized to either PLD 
(50 mg/m2 every 28 days) or PTX (175 mg/m2 every 21 days). 
Preliminary analysis of the data revealed that there were no 
significant differences in response rates, PFS, OS, or rate 
of adverse events. However, since the study was suspended 
because of poor accrual as paclitaxel became incorporated 
into first-line chemotherapy, no definitive analysis was car-
ried out.
In the Gordon et al study,107 whose updated findings 
were presented in 2004,108 ovarian cancer patients recurring/ 
progressing after front-line chemotherapy were randomized 
to receive PLD (50 mg/m2 every 28 days) vs TPT (1.5 mg/m2 
days 1 to 5, every 21 days): in platinum resistant disease 
Table 9 Randomized studies with pegylated liposomal doxorubicin (PLD) alone or in combinations in salvage setting
Author Pts  
(No.)
Drugs/dose No. RR  
(%)
PFS  
mts
OS  
mts
% Grade 3/4 toxicity/patient
Hgb Neu PLT HFS
O’Byrne106 REC  
(214)
PLD (50 mg/m2) q28  
vs  
PTX (175 mg/m2) q21
107  
107
17.8  
22.4
5.4  
6.0
11.4  
14.0
– – – –
Gordon107,108 RES  
(255)  
 
SEN  
(219)
PLD (50 mg/m2) d1, q28  
vs  
TPT (1.5 mg/m2) d1–5 q21  
PLD (50 mg/m2) d1, q28  
vs  
TPT (1.5 mg/m2) d1–5, q21
130  
125  
109  
110
12.3  
6.5  
28.4  
28.8
2.3  
3.4  
7.2  
5.8*
8.9  
10.3  
27  
17.5*
5  
28
12  
 
77
1  
 
34
23  
 
0
Mutch109 RESa  
(195)
PLD (50 mg/m2) d1, q28  
vs  
GEM (1,000 mg/m2) d1,8, q21
96  
99
8.3  
6.1
3.6  
3.1
12.7  
13.5
2.1  
3.0
18.7  
 
38.4
5.2  
 
6.1
10.4  
 
0
Ferrandina110 RESb  
(153)
PLD (40 mg/m2) q28  
vs  
GEM (1,000 mg/m2) d1,8,15 q28
76  
77
16 
29
4.0  
5.0
14  
12.7*
5 
 
7
6  
 
23
0  
 
5
5  
 
0
Vergote112  
ASSIST-1
RESc  
(461)
PLD (50 mg/m2) d1, q28 or TPT  
1.5 mg/m2 d1–5 q21  
vs  
CAN (1,000 mg/m2) q21
229  
 
232
10.9 
4.3
4.3*  
2.3
13.5*  
8.5
–  
–
–  
 
 
–
–  
 
 
–
–  
 
 
–
Vergote113  
ASSIST-5
RESc  
(125)
PLD (50 mg/m2) d1  
CAN (1000 mg/m2) q28  
vs  
PLD (50 mg/m2) d1, q28
65  
60
12.3d  
8.3
5.6d  
3.7
–  
–
–  
–
–  
 
 
–
–  
 
 
–
–  
 
 
–
Monk117  
OVA-301
ALL  
(672)
PLD (30 mg/m2) d1  
TRAB (1.1 mg/m2) d1,q21  
vs  
PLD (50 mg/m2) q28
335  
337
28.0* 
19.0
7.3*  
5.9
20.5e  
 
19.4
14.0  
6.0
63.0  
 
22.0
18.0  
 
 
2.0
4.0  
 
 
20.0
SEN  
(430)
PLD (30 mg/m2) d1  
TRAB (1.1 mg/m2) d1,q21  
vs  
PLD (50 mg/m2) q28
–
 
 
–
35*  
 
 
23
9.2*  
 
 
7.5
–  
 
 
–
–  
 
 
–
–  
 
 
–
–  
 
 
–
–  
 
 
–
Abbreviations: CAN, canfosfamide; GEM, gemcitabine; HFS, hand–foot syndrome; Hgb, anemia; Neu, neutropenia; OS, overall survival; PFS, progression-free survival; PLT, 
platelet toxicity; PTX, paclitaxel; REC, not otherwise specified recurrent disease; RES, platinum-resistant recurrent disease; RR, response rate; SEN, platinum-sensitive recurrent 
disease; TRAB, trabectedin; q, every; d, day.
*statistically significant.
aup to 2 prior regimens allowed; bplatinum resistance = recurrence/progression within 12 months from primary chemotherapy; cpatients progressed on 2nd line treatment; din 
the subgroup of platinum refractory/resistant (n = 75), the combination achieved a high response rate (15.0% vs 5.7%) and a longer PFS (median = 5.6 months vs 2.9 months) 
(HR = 0.55; P = 0.042); eresults from interim analysis.Therapeutics and Clinical Risk Management 2010:6 473
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(n = 255) no significant difference was seen in response 
rate, PFS, or OS between the two treatment arms, while 
in platinum-sensitive patients (n = 219), median PFS and 
OS were significantly prolonged in PLD- vs TPT-treated 
patients (P value = 0.037, and P value = 0.008, respectively). 
More mature survival analysis confirmed the long-term 
advantage for platinum-sensitive patients receiving PLD vs 
TPT (median OS = 27 months vs 17.5 months, hazard ratio 
[HR] = 1.432, P value = 0.017).108 Moreover, for partially 
platinum-sensitive disease (n = 122), the HR favored PLD 
vs TPT (HR = 1.58, P value = 0.021).
The toxicity profiles of the two drugs were completely 
different, grade 3/4 hematological toxicity occurring more 
frequently and more severely in TPT vs PLD: in particular, 
severe neutropenia was documented in 77% of TPT- vs 12% 
of PLD-treated patients (P  0001), and thrombocytopenia 
was found in 34% of TPT vs 1% of PLD cases (P  0.001). 
No case of severe HFS was documented in the TPT arm 
while it was registered in 23% of PLD-treated patients (P  
0.001). Although compliance to fulfil the EORTC-QLQ-C30 
questionnaire was poor, thus leaving at 12 weeks of treatment 
only 200 patients available for comparison, there were no 
differences in terms of functional and symptom scale QoL 
scores between the two arms.
Two more recent phase III trials commpared PLD with 
GEM in recurrent platinum-resistant ovarian cancer patients: 
Mutch et al109 studied 195 cases experiencing progressive 
disease within 6 months of completing first-line platinum-
based therapy: patients were randomly assigned to either PLD 
(50 mg/m2 every 28 days) or GEM (1000 mg/m2, days 1, 8, 
every 21 days) until progression or undue toxicity. Almost 
36% of cases in the overall series had already received 2 
prior regimens; moreover, response was assessed on the 
basis of CA15 levels only, in approximately 36% of cases. 
There was no difference in the response rate between the 
two treatment arms; median PFS was 3.6 and 3.1 months in 
PLD vs GEM-treated arms, respectively, while median OS 
was 12.7 vs 13.5 months: none of the survival end-points 
showed a statistically significant difference between the two 
treatment groups.
In contrast to the study of Mutch et al,109 the MITO-3 trial 
on behalf of the Multicenter Italian Trials in Ovarian cancer 
(MITO) Group was conducted on patients who recurred/ 
progressed within 12 months from the completion of primary 
treatment and had received only one platinum/paclitaxel 
regimen;110 the study included 153 cases (86 patients with 
a PFI  6 months and 67 patients with a PFI within 7 to 12 
months) who were randomized to PLD (40 mg/m2, every 
28 days) vs GEM (1,000 mg/m2, d1,8,15, every 28 days). 
In the whole series the response rate was 16% in PLD vs 
29% in GEM treated patients (P value = 0.066). No sta-
tistically significant difference was documented between 
the two treatment arms in terms of PFS; however, a more 
favorable OS was registered in the PLD- vs the GEM-treated 
arm (median OS = 14 months vs 12.7 months, respectively; 
P value = 0.048). With the limits inherent in the small sample 
series, the survival advantage reported with PLD over GEM 
was maintained in the subgroup of partially sensitive patients 
(P value = 0.016).
Higher global QoL scores especially for physical and 
emotional findings and fatigue were found in PLD-treated 
patients at the first and second post-baseline assessments, 
and this is likely to reflect the profile of toxicity: indeed, 
hematological toxicity was negligible, with only 6% of grade 
3/4 neutropenia compared to 23% in the GEM arm. More-
over, severe HFS was documented in only 5% of cases, in 
line with the results of previously reported phase II studies 
(see Table 6).
Very recently, the activity of canfosfamide (CAN) 
  (Telcyta®), a glutathione analog prodrug which, upon 
activation by glutathione S-transferase P1-1, is able to 
induce cellular apoptosis,111 has been tested with a control 
arm represented by PLD or TPT in platinum-resistant recur-
rent ovarian cancer patients who had already progressed 
on second-line treatment with PLD or TPT112 (ASSIST-1, 
NCT00057720). Patients (n = 461) were randomized to 
receive PLD (50 mg/m2 every 28 days) or TPT (1.5 mg/m2, 
days 1 to 5, every 21 days) vs CAN (1000 mg/m2 every 
21 days). The overall response rate was higher in the control 
arm vs CAN (10.9% vs 4.3%,   respectively), as was also 
median PFS (4.3 months vs 2.3 months, P value = 0.01). An 
overall survival advantage favoring the control arm vs CAN 
was also documented; in particular, median OS was 13.5 
months in the control (14.2 months in PLD, 10.8 months in 
TPT) vs 8.5 months in the CAN arm (P  0.01). Based on 
these results, which basically represent the first evidence 
from a randomized study of prolongation of OS with third-
line treatment, a phase III trial (ASSIST-5, NCT00350948) 
comparing the combination PLD/CAN vs PLD alone 
had been planned based on the demonstration that PLD 
might favor glutathione S-transferase expression, thus 
potentially increasing cancer cell susceptibility to CAN: 
patients were randomized to receive PLD (50 mg/m2) plus 
CAN (1000 mg/m2) every 28 days, vs PLD (50 mg/m2 
every 28 days). The primary end-point of the study was 
originally represented by OS and the planned sample size Therapeutics and Clinical Risk Management 2010:6 474
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corresponded to 244 platinum resistant   recurrent OvCa 
patients who had already been administered at least 2 
previous lines of chemotherapy. However, the study was 
temporarily suspended while waiting for the data from the 
ASSIST-1 study, and, at the time enrolment was re-started, 
the primary end-point had been replaced by PFS, while 35 
out of 125 patients enrolled had not received the planned 
drug.113 In the intention to treat analysis, no difference 
emerged between the two treatment arms in terms of 
response rate and PFS; however, when considering the 
subgroup of platinum-refractory and primary platinum-
resistant patients, a statistically significant advantage in 
favor of the combination was observed in terms of response 
rate (15.0% vs 5.7%) and PFS (median 5.6 months vs 2.9 
months, HR = 0.55, P value = 0.042). A trend for a longer 
OS was also observed in the combination vs single agent 
arm (median OS = 11.8 months vs 7.8 months), although 
statistical significance was not reached. While the hema-
tological toxicity was generally higher in the combination 
arm vs PLD alone, the rate of grade 2/3 HFS was lower 
in PLD/CAN than PLD alone (9% vs 21%, respectively), 
although the reasons for the protection conferred by the 
combination remain unclear. These data are the first to report 
a potential advantage related to the use of a doublet in the 
poor-prognosis subset of platinum-resistant OvCa patients, 
and need to be confirmed in the final analysis.
At this time, available data support the phase II-derived 
suggestions that in platinum-resistant disease none of the 
currently most frequently used drugs, such as PLD, GEM, or 
TPT, shows superiority over the others in terms of response 
rate and survival; in this context the 3-week schedule of 
administration of PLD at 40 mg/m2 seems to offer the most 
favorable toxicity profile, which is likely to sustain the 
achievement of better QoL scores, at least in comparison 
to GEM.110
Among the most intriguing novel drugs, trabectedin 
(TRAB) (ET743; Yondelis®), the marine compound derived 
from Ecteinascidia turbinata, has become relevant for 
treatment of sarcomas and other solid tumors.114 TRAB has 
a unique mechanism of action, in that, unlike most other 
agents, it binds to the minor groove of DNA thus affecting 
a variety of transcription factors, cell proliferation, and the 
nucleotide excision repair system. In addition, TRAB inhib-
its the MDR-1 gene coding for the protein responsible for 
chemoresistance.114 Based on safety and efficacy results from 
phase I/II studies in several advanced malignancies, including 
resistant and particularly platinum-sensitive recurrent OvCa 
patients,115,116 a phase III trial (OVA-301, NCT00113607) 
has been planned to compare PLD 50 mg/m2 every 28 days 
with the combination PLD 30 mg/m2 and TRAB 1.1 mg/ m2 
every 21 days, in ovarian, peritoneal, and tubal cancer 
recurring/progressing after first-line chemotherapy,117 with 
Table 10 Randomized studies with pegylated liposomal doxorubicin (PLD) in combination with platinum in salvage setting
Author Pts Drugs/dose No. pts RR  
(%)
PFS  
mts
OS  
mts
% Grade 3/4 toxicity/patient
Hgb Neu PLT HFS
Alberts119,a  
SWOG SO200
SEN  
6–24 mts
PLD (30 mg/m2) d1  
JM8 (AUC 5) d1, q28  
vs  
JM8 (AUC 5) d1, q28
31  
 
 
30
52  
 
 
29
12*  
 
 
8
26*  
 
 
18
16  
 
 
0
48.0  
 
 
3.0
39.0  
 
 
0
3.0  
 
 
0
Markman120  
SWOG SO200
SEN  
6–24 mts
PLD (30 mg/m2) d1  
JM8 (AUC 5) d1, q28  
vs  
JM8 (AUC 5) d1, q28
31  
 
 
30
59*  
 
 
28
12*  
 
 
8
31  
 
 
18
–  
 
 
–
–  
 
 
–
–  
 
 
–
–  
 
 
–
Linardou121,b SEN  
6 mts
PLD (45 mg/m2) d1  
JM8 (AUC 5) d1, q28  
vs  
PTX (175 mg/m2) d1  
JM8 (AUC 5) d1, q21
93  
 
 
96
51  
 
 
58
11.7  
 
 
10.8
24.4  
 
 
30.4
–  
 
 
–
35.0  
 
 
30.0
12.0  
 
 
12.0*
0  
 
 
–
Pujade-Lauraine122  
CALYPSO  
(EORTC 55051)
SEN  
6 mts
PLD (30 mg/m2) d1  
JM8 (AUC 5) d1, q28  
vs  
PTX (175 mg/m2) d1  
JM8 (AUC 5) d1, q21
467  
 
 
509
–  
 
 
–
11.3*  
 
 
9.4
–c  
 
 
–
–  
 
 
–
35.0  
 
 
46.0
16.0  
 
 
6.0
1.0  
 
 
1.0
*statistically significant. 
aprematurely closed for slow accrual; brandomized phase II study; ctoo early to be reported.
Abbreviations: HFS, hand–foot syndrome; Hgb, anemia; JM8, carboplatin; Neu, neutropenia, PFS, progression-free survival; PLT, platelet toxicity; PTX, paclitaxel; RR, response 
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the exclusion of refractory cases; patients were stratified 
according to ECOG PS (0–1 vs 2), and platinum sensitivity 
(PFI  6 months vs PFI  6 months). Originally, the primary 
end-point was the OS but it was later amended to PFS at the 
end of 2006. Secondary end-points included OS, response 
rates, safety, and pharmacokinetics. Overall, 672 patients 
were enrolled (337 allocated to PLD/TRAB vs 335 allocated 
to PLD). In the whole series the response rate as assessed 
by independent radiology review by Response Evaluation 
Criteria In Solid Tumors (RECIST) was significantly higher 
in PLD/TRAB than PLD alone group, as was also median 
PFS (HR = 0.79, P value = 0.019). However, in platinum-
resistant cases (n = 242), no difference was observed in the 
combination vs PLD alone in terms of response rate (13.4% 
vs 12.2%, respectively), and PFS, while a clear advantage 
favoring the combination compared to single-agent PLD was 
evident in platinum-sensitive disease (n = 430) (response 
rate 35.3% vs 22.6%, P = 0.0042; median PFS 9.2 months 
vs 7.5 months; HR = 0.73, P = 0.017). In the context of 
platinum-sensitive disease, these findings were also evident 
in the subset of partially platinum-sensitive disease with 
median PFS of 7.4 vs 5.5 months in PLD/TRAB vs PLD 
arm (HR = 0.65, P = 0.0152).
Grade 3/4 anemia, neutropenia and thrombocytopenia 
were documented in 14%, 63%, and 18% of PLD/TRAB 
cases, and were significantly more frequent compared to 
PLD alone. Among non-hematological toxicities, grade 
3/4 elevation of sGOT, and sGPT was reported in 38% 
of cases: they were described as of short duration, and of 
decreased magnitude with succeeding cycles. On the other 
hand, HFS was documented in 4% of the PLD/TRAB arm 
compared to 20% in the PLD alone arm. In spite of the 
increased hematological toxicity in the PLD/TRAB group 
there was no deterioration of QoL/patient reported outcome 
(PRO), QLQ-C30 and OV28 and EQ-5D scales.118 Based on 
these results, which support the PLD/TRAB combination 
as the most effective non-platinum based combination in 
platinum-sensitive disease, the combination PLD (30 mg/m2) 
and TRAB (1.1 mg/m2), every 3 weeks, has been recently 
approved by the EMEA (September 2009), and is currently 
submitted for FDA approval for treatment of patients with 
relapsed platinum-sensitive OvCa.
Among platinum combinations, which are well estab-
lished to be superior to platinum agents alone in the recur-
rent setting, PLD/JM8 regimens seem to offer the most 
effective therapeutic index compared to combinations with 
taxanes and gemcitabine,81,82 as also suggested by phase 
II studies. Indeed, the SWOG SO200 trial119 compared 
PLD/JM8 combination to JM8 alone, but was prematurely 
stopped because of slow accrual probably related to the 
introduction of PTX as the JM8 partner in the salvage set-
ting; however, final re-  analysis of survival analysis has been 
very recently published,120 showing that with longer follow 
up and additional events, a statistically significant improve-
ment of PFS with the combination has been registered, 
although the previously reported more favorable OS could 
no longer be detected. Interestingly, for unknown reasons, 
the association of PLD with JM8 drastically reduced the 
rate of hypersensitivity reactions compared to JM8 alone 
(9% vs 0%, P = 0.0008).
The other randomized trials tested PLD/JM8 regimen 
against PTX/JM8 doublet: in particular, the phase II random-
ized study by Linardou et al121 documented no difference 
between the two arms in terms of response rate and PFS, 
probably because of the small sample size, while confirming 
the very favorable toxicity profile for the combination, which 
resulted in a lower rate of severe thrombocytopenia and, more 
importantly, in no case of severe neurotoxicity.
At the 2009 ASCO meeting the Gynecologic Cancer 
Intergroup presented the preliminary results of CALYPSO 
trial (EORTC 55051),122 a randomized phase III study which 
accrued 976 OvCa patients recurring after 6 months after 
their first- or second-line platinum based therapy. Patients 
were randomized: the control group received JM8 AUC 5 
and PTX 175 mg/m2 every 21 days and the experimental 
group received JM8 AUC 5 and PLD 30 mg/m2 every 
28 days. The trial showed a statistically significant supe-
riority of PLD/JM8 over PTX/JM8 combination in terms 
of PFS. Moreover, the superiority of PLD/JM8 was also 
confirmed in the subset of partially platinum-sensitive 
disease.123 With a median follow up of 21 months and 308 
events, data on OS were be reported early. While grade  2 
HFS was documented in 13% of the PLD/JM8 vs 2% of 
the PTX/JM8 arm, lower rates of grade 2/3 neurotoxicity 
were reported in the experimental than in the standard arm 
(5% vs 28%, respectively). Interestingly, severe hypersen-
sitivity reactions occurred less frequently in PLD/JM8 than 
in PTX/JM8 group (2% vs 9% ).
While waiting for the mature OS data from the 
CALYPSO trial, it can be reasonably stated that the PLD/
JM8 combination represents a valid alternative to other 
platinum-based regimens in recurrent platinum-sensitive 
OvCa especially for patients whose QoL is recognized to 
be heavily compromised by alopecia, or who had experi-
enced or had not yet been rescued from taxane-induced 
neurotoxicity.Therapeutics and Clinical Risk Management 2010:6 476
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Attempts to include PLD in front-line treatment have 
also been attempted: in particular, with the aim of improving 
PTX/JM8 efficacy, sequential doublets or triplet combina-
tions including PLD have been investigated based also on the 
very favorable and not overlapping toxicity profile. The use of 
4 cycles of standard PTX/JM8 (175 mg/m2, AUC 6, every 21 
days) followed by 4 cycles of PLD/JM8 (40 mg/m2, AUC 6, 
every 21 days) has been first investigated by Potamianou 
et al124 in a phase II study including 41 patients. At the end 
of the 8 courses the response rate was 66%, and median PFS 
was 20 months. Toxicity mainly consisted of neutropenia, 
which occurred in 48.7% of patients at the end of JM8/PTX 
and 63.8% at the end of PLD/JM8 treatment. There was no 
undue or unexpected non-hematological toxicity, but grade 
2 and 3 neurotoxicity after PTX/JM8 was registered in 9% 
and 34.1% of patients, respectively. The potential efficacy of 
triplets and sequential doublets has been also investigated in 
the GOG182/ICON5 randomized trial,125 which represents 
the largest cooperative effort attempted worldwide by the 
Gynecologic Oncology Group in the US, and the Medical 
Research Council in the UK on behalf of the International 
Collaborative Ovarian Neoplasm (ICON) Group. The 
GOG182/ICON5 trial enrolled 4312 stage III/IV patients 
who were randomized to 5 arms including the standard 
treatment 1) JM8 AUC 6, PTX 175 mg/m2 every 21 days, 
8 cycles, vs 2 triplets; 2) JM8 AUC 5, PTX 175 mg/m2, 
GEM 800 mg/m2 days 1, 8, every 21 days, 8 cycles; 3) JM8 
AUC 5, PTX 175 mg/m2, every 21 days plus PLD 30 mg/m2, 
every other cycle, 8 cycles, or 2 sequential doublets: 4) JM8 
AUC 6, TPT 1.25 mg/m2 days 1 to 3, 4 cycles, followed by 
JM8 AUC 6, PTX 175 mg/m2, 4 cycles; 5) JM8 AUC 6, GEM 
800 mg/m2, days 1, 8 every 21 days, 4 cycles followed by 
JM8 AUC 6, PTX 175 mg/m2, 4 cycles.
Despite the documentation of increased hematological 
and non-hematological toxicity in the triplet regimens, there 
was no PFS or OS advantage with sequential doublets or with 
triplets compared with the control arm.
In the front-line setting, mature results from the MITO-
2 (NCT00326456)126,127 trial are eagerly awaited; this 
study, which first investigated the combination PLD/JM8 
(30 mg/m2, AUC = 5, every 21 days) vs the standard treat-
ment, has randomized 820 stage IC/IV ovarian cancer patients 
since January 2003 to November 2007. The primary objective 
was PFS, while secondary objectives were OS, response rate, 
toxicity and QoL. Data presented at the 2009 ASCO meeting 
documented the equivalence of the two treatment arms in 
terms of response rate (59.0% in the standard vs 57.0% in 
the experimental arm, P = 0.70).128 As of March 2009, with 
a median follow up of 35 months, 530 events for PFS and 
269 deaths were documented; therefore survival data can-
not be considered mature enough for final analysis, which 
will be hopefully available in 2010. As expected, the pattern 
of toxicity differed between the two groups: severe anemia 
and thrombocytopenia were more frequently detected in 
PLD/JM8 vs the standard arm (10% vs 4%, P  0.001, for 
anemia) (16% vs 2%, P  0.001, for thrombocytopenia). 
On the other hand, grade  3 neurotoxicity was registered 
in 3% of standard vs 0.3% in the experimental treatment 
(P = 0.004). Finally, alopecia (any grade) occurred in 63% 
of cases allocated to the standard vs 14% allocated the 
experimental arm (P  0.001).
PLD and target-based agents
Given the relevance of PLD alone or in combination with 
platinum as well as non-platinum agents in almost all clinical 
settings of ovarian cancer, it is not surprising that attempts 
are ongoing to study combinations of this drug with target-
based agents: the rationale of this approach is represented 
by the enormous potential inherent in classes of drugs with a 
different mechanism of action. Moreover, the availability of 
target-based agents at an advanced stage of clinical develop-
ment, and therefore with a well known spectrum of activity 
and toxicity, has fuelled great enthusiasm for exploring their 
association with PLD. Among the most appealing classes of 
biological drugs, the angiogenesis inhibitors seem to be the 
most promising: in particular, several phase II trials have 
shown the activity of bevacizumab (BEV) (Avastin®), the 
monoclonal antibody against vascular endothelial growth 
factor (VEGF), in platinum-resistant and -sensitive dis-
ease.129 Preliminary results from an ongoing phase II study 
have been recently presented at the 2009 ASCO meeting, 
on the PLD/BEV combination in second-line treatment of 
OvCa patients with a PFI  6 months and with  3 previ-
ous regimens.130 The study was started in 2007 and aimed at 
recruiting 48 patients. PLD (30 mg/m2 every 21 days) was 
administered alone at the first cycle, and then with BEV 
(15 mg/kg every 21 days) for the following 6 cycles or 
until progression. In the 21 patients available for analysis, 
response was documented in 14.3% of cases according to 
the RECIST criteria, and in 8 out of 14 cases (57.1%) who 
had elevated Ca125 levels at enrolment. In 62% of cases 
PFS duration exceeded 18 weeks. Interestingly, the phar-
macokinetics measures obtained after 1 hour, and at day 
7 and day 21 of the first 2 cycles did not show any BEV-
induced modification of PLD pharmacokinetics. Grade 3 
HFS was registered in 5% of cases, and PLD dose reduction Therapeutics and Clinical Risk Management 2010:6 477
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was required in 33% of cases, while grade 3 hypertension 
and BEV reduction  10% was reported in 15% of cases. 
With the aim of reducing the rate/severity of side effects, 
a weekly regimen of PLD/BEV (PLD 10 mg/m2 and BEV 
2 mg/kg days 1, 8, 15, every 28 days, for at least 3 cycles) 
was investigated in 30 recurrent OvCa patients who had been 
heavily pre-treated.131 According to the Gynecologic Cancer 
Intergroup criteria, an overall response rate of 45% was 
achieved in 26 evaluable patients with a clinical benefit in 
75% of cases. On the basis of the RECIST criteria, response 
was achieved in 38.4% of cases with disease stabilization 
in 34.6%. No severe hematological toxicity was observed, 
and the only cases experiencing gastrointestinal perfora-
tion were treated conservatively. HFS was documented in 
13.6% and required treatment in only one case. Overall, the 
weekly regimen seems well tolerated although the potential 
cumulative cardiovascular side effects of the two drugs need 
to be explored in a larger series. A large phase II random-
ized study (AURELIA, NCT00976911) is ongoing, which 
recruits patients with recurrent platinum-resistant ovarian, 
fallopian tube and peritoneal cancer, who are randomized to 
standard treatment (PTX, or TPT, or PLD 40 mg/m2 every 
28 days) vs the experimental arm in which BEV 10 mg/m2 
bi-weekly or 15 mg/m2 every 21 days is added to the same 
drugs. Among novel VEGFR kinase inhibitors, vandetanib 
is currently being investigated in combination with PLD in 
recurrent OvCa (NCT00862836).
The interest in other angiogenesis inhibitors is shown 
by the efforts to study molecules acting on different targets, 
such as volociximab (VOL). This is a chimeric monoclonal 
antibody able to directly target α5/β1 integrin, a protein 
characterizing the activated endothelial cells, thus preventing 
its interaction with the extracellular fibronectin and disrupt-
ing tumor neoangiogenesis.132 A phase II study by Vergote 
et al133 has been carried out in recurrent OvCa patients who 
had already been administered up to 2 lines of chemotherapy; 
patients received PLD 40 mg/m2 every 28 days (n = 15), or 
PLD 40 mg/m2, every 28 days and VOL 15 mg/m2 biweekly 
(n = 15) or PLD 40 mg/m2 every 28 days and VOL 15 mg/m2 
weekly (n = 15). According to the PFS duration documented 
in each arm, an increasing number of cases would be enrolled 
in more favorable arms. 66 patients were enrolled in the first 
arm while 34 and 27 patients were allocated to the remain-
ing groups. Median PFS was 27.5 weeks in the first arm, 
18 weeks in the second and 31.6 weeks in the third, thus 
suggesting no superiority of the combination vs PLD alone. 
Severe side effects have been documented in 5% of cases 
in each treatment arm and, interestingly, in this study also, 
the addition of the target-based agent did not seem to alter 
PLD pharmacokinetics.
A summary of the ongoing trials investigating the com-
bination of PLD with other growth factor receptor inhibitors 
such as IMC-3G3, an inhibitor of PDGF-R (NCT00913835), 
panitumumab (an EGF-R blocker) (NCT00861120), and 
pazopanib (which interferes with VEGF-R1,2,3 kinase, 
PDGF-R and c-kit oncogene product) (NCT01035658) can 
be found at the www.clinicaltrials.gov.
Besides the attempts to study the association of PLD 
with drugs interfering with the angiogenic and growth factor 
driven mitogenic processes, other novel biological targets 
crucial for cancer cell biology have been considered for 
designing PLD/target based therapy: for instance farletu-
zumab (MORAB-003), an inhibitor of folate receptor-α, is 
under investigation combined with PLD and JM8 in recur-
rent platinum-sensitive recurrent OvCa (NCT01004380). 
Moreover, based on preclinical studies and encouraging 
phase I data showing the absence of any interference of 
bortezomib (BOR; Velcade®), a proteasome inhibitor, with 
PLD pharmacokinetics,134 preliminary results of a phase II 
study combining the two drugs were presented at the 2008 
ASCO meeting;135 recurrent platinum-resistant (n = 15), 
and -sensitive (n = 15) OvCa patients were administered PLD 
30 mg/m2 and BOR 1.3 mg/m2 days 1, 4, 8, 11 every 21 days. 
Responses were seen only in the platinum-sensitive disease 
group which proceeded to the second step of enrolment.
Although all these data are very preliminary, it seems 
that quite tolerable combinations of PLD with target-
based agents can be used without interfering with PLD 
  pharmacokinetics.
PLD: toxicity issues
The very favorable PLD toxicity profile is widely recognized 
as the advantage of this drug, which does not accumulate 
in normal tissues and especially in cardiac muscle, thus 
eliminating the cardiotoxicity commonly associated with 
conventional doxorubicin administration.136 However, some 
adverse side effects have to be taken into account: acute 
hypersensitivity reaction, characterized by flushing, head-
ache, facial edema, back pain, rigors, dyspnea, hypotension 
and chest/throat tightness can occur during drug infusion (and 
differently from hypersensitivity reactions with other drugs 
which generally are documented after a previous exposure), 
they can be registered even during the first administration. 
PLD-related reactions are seen in about 6.8% of patients; 
however, if they are not documented initially, they rarely 
occur in subsequent cycles.14 Moreover, hypersensitivity Therapeutics and Clinical Risk Management 2010:6 478
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reactions seem to depend on the infusion rate, and can 
therefore be prevented, in principle, by administering the 
drug at an initial rate of 1 mg/min. Muco-cutaneous toxicity 
is the most frequent PLD-related side effect, and represents 
the most important dose-limiting toxicity.19 In particular, 
palmar-plantar erythrodysesthesia, also known as HFS and 
originally described as associated with 5-fluorouracil infu-
sion, represents a distinctive toxic reaction to PLD adminis-
tration. Pathogenesis remains unclear, although it is generally 
accepted that the prolonged accumulation of PLD in areas 
where subclinical trauma occurs (due to friction, tight-fitting 
clothing or shoes, repeated skin pressure or chemical insults), 
leading to inflammation and subsequent altered vascular per-
meability, might play a relevant role.137 It has been suggested 
that PLD transport by sweat could lead to an easy localization 
of the drug into the stratum corneum where free radicals are 
produced and HFS can be induced.138
HFS is characterized by paresthesia of the outer extremi-
ties occurring 2 to 12 days after chemotherapy administration, 
and is followed 3 to 4 days later by patch erythema, edema, 
and desquamation of hands and soles. The natural history of 
HFS is often self-limiting with resolution within 1 to 5 weeks 
from stopping treatment. However, some cases develop 
blistering and ulceration which can limit daily functions and 
reduce patient quality of life. Recently, the investigation of 
factors favoring the occurrence of HFS during PLD treatment 
has been carried out in a very large series of recurrent ovarian, 
peritoneal and fallopian tube cancer patients: the number of 
PLD cycles and doses  50 mg/m2 as well as the concomitant 
occurrence of neutropenia, and peripheral neuropathy were 
predisposing factors for HFS.101 Moreover, the incidence of 
HFS was higher in patients receiving 3 lines of previous 
chemotherapy lines regardless of chemotherapeutic agents 
used. Surprisingly, the proportion of cases who suffered PPE 
was higher in cases of cooling mechanism adoption,101 while 
patient age and mean body mass index did not affect HFS 
development, confirming previously published results.139 
Besides the cumulative dose, the schedule of administration 
also seems to be an important risk factor: in particular, it 
has been suggested that the 3-week schedule may coincide 
with the interval of epidermal turnover, a phenomenon that 
would thus emphasize the potential PLD-induced keratino-
cyte damage.140 Patient education to avoid risk factors by 
preventing mechanical, physical, or chemical skin insults, 
and to recognize early the initial signs/symptoms of skin 
toxicity is relevant. More specifically, the use of ice pack 
cooling of hands and feet associated with consumption of 
iced liquids during chemotherapy administration has been 
empirically explored,141 as well as the administration of 
corticosteroids, pyridoxine supplement, topical application 
of dimethylsulfoxide, and emollient or moisturizing lotions 
which are often used in clinical practice.142 However, with the 
exception of pyridoxine supplement which has been recently 
tested in a phase III study and shown not to confer any advan-
tage compared to placebo in terms of HFS prevention,143 the 
true efficacy of the other approaches has not been proven in 
prospective trials. Apart from the studies suggesting that the 
bi-weekly schedule, or the 4-weekly administration of PLD at 
doses of 40 mg/m2 are associated with negligible if any severe 
HFS (see Table 6), a randomized phase II trial in metastatic 
breast cancer has also shown that by reducing PLD dose 
intensity to 10 mg/m2/week, HFS tends to be mild or modest 
in the vast majority of cases.144 Recently, an international 
panel of experts was convened to develop recommendations 
for management of PLD-associated HFS according to the 
grade of symptoms and clinical findings;145 however, phase 
III trials are urgently needed to support the rigorous adoption 
of any of these previously cited interventions.
Conclusions
The pegylated liposomal formulation of doxorubicin, because 
of its unique and favorable toxicity profile, has greatly 
expanded the clinical applications of the parent compound: 
indeed, whether used alone or in combination with non-
platinum and platinum agents, PLD has been introduced 
in the management of almost all clinical settings in OvCa 
patients.
In particular, results from phase II and phase III random-
ized trials have led to FDA approval of PLD in the salvage 
treatment of recurrent disease; moreover, the upcoming 
mature results of the CALYPSO trial suggest that PLD/
carboplatin combination is a very valid option in recurrent 
platinum-sensitive disease especially in patients who had 
experienced or had not yet been rescued from taxane-induced 
neurotoxicity or just refuse to tolerate alopecia. The MITO-2 
final results might lead to the replacement of paclitaxel as the 
carboplatin partner in front-line treatment, or at least provide 
a useful alternative to carboplatin/paclitaxel depending on 
patient performance status and preference. Meanwhile efforts 
will continue in combining PLD with target-based agents 
which have already shown preliminary promising activity 
in ovarian malignancies, and do not seem to alter the unique 
and advantageous pharmacokinetics of PLD.
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